Navigation Links
Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
Date:4/20/2009

an amendment to the submission once we have complete two-year data on the primary patient cohort," said Gary F. Burbach, president and chief executive officer of Thoratec.

In December 2008, Thoratec received approval from the FDA to end randomization in the trial, based on a pre-specified interim analysis of 67 percent of the first 200 patients that showed that patients implanted with the HeartMate II achieved statistically superior outcomes versus those in the control group who were implanted with the HeartMate XVE. Based on that analysis, the study's Data Safety Monitoring Board concurred with Thoratec's recommendation to eliminate randomization for patients enrolled in the trial under FDA-approved CAPs.

Patients in the trial were randomized to the HeartMate II or the HeartMate XVE -- currently the only device approved for DT -- on a 2-1 basis, respectively. The primary endpoint at two years is survival while remaining free from stroke and the need for reoperation for pump repair or replacement. Secondary endpoints included adverse events, functional status, hospitalization, assessment of neuro-cognitive function and patient quality of life.

"The data from the trial demonstrate that the HeartMate II is superior to the XVE, based on device performance and the primary patient outcome of two-year survival free from stroke and reoperation for device replacement. The data also showed that key adverse events, such as infection, sepsis and right heart failure, were significantly lower for the HeartMate II versus the XVE. As a result, this submission seeking FDA approval for Destination Therapy is an important milestone in Thoratec's mission to bring breakthrough therapies and new hope to the thousands of patients and their families suffering from advanced heart failure, as well as the clinicians who work tirelessly to treat them," Burbach said.

"The commercial experience of the HeartMate II for BTT
'/>"/>

SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. Thoratec Presentation at Bear Stearns Conference To Be Webcast
3. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
4. Thoratec Presentation at JP Morgan Conference to be Webcast
5. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
6. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
7. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
8. Thoratec Presentation at J.P. Morgan Conference to be Webcast
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... has named Todd Creech as Chief Financial Officer and ... Creech has been fulfilling both positions as a consultant ... http://photos.prnewswire.com/prnh/20110214/FL47222LOGO ) "Todd comes to ... leadership roles and has demonstrated great success in helping ...
... Even with radical advances in medicine and technology ... penile extender system is still the most effective ... QuickExtenderPro.com, the leading provider of penis extender ... With the emergence of the penile extender, procedures such ...
... EXTON, Pa., Feb. 11, 2011 ViroPharma Incorporated (Nasdaq: ... chief executive officer of ViroPharma, will present at the Leerink ... ET on Thursday, February 17, 2011.  The conference is being ... ViroPharma,s presentations will be webcast live for investors through ...
Cached Biology Technology:Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 2Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 3QuickExtenderPro.com Penis Extender Device Engineered for Quick, Safe and Effective Alternative to Penis Enlargement Surgery 2ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference 2
(Date:4/18/2014)... techniques like X-ray crystallography and nuclear magnetic resonance imaging ... of molecules, but such efforts have long been hampered ... a specific molecule and often in ordered and crystalized ... impossible to peer into the structure of most molecules. ... be a thing of the past. , A ...
(Date:4/18/2014)... and comet impacts can cause widespread ecological havoc, killing ... scales. But new research from Brown University shows that ... at the time of an impact. , A research ... fragments of leaves and preserved organic compounds lodged inside ... The material could provide a snapshot of environmental conditions ...
(Date:4/17/2014)... chili peppers. Information about archaeological remains of ancient chili ... appearance of words for chili peppers in ancient dialects ... highlight the value of multi-proxy data analysis. Their results ... papers presented in a special feature issue of the ... on plant and animal domestication edited by Dolores Piperno, ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Chickens to chili peppers 2Chickens to chili peppers 3
... Earthwatch met in Panama from Mar. 1-5 to present mid-term ... to identify and respond to the impacts of climate change. ... global team of bank employees ,climate champions, in ... program of its kind has so far: , Found ...
... $10.2 million commitment from the Robertson Foundation to create ... Duke Medicine,s pioneering cell therapy research and treatment programs ... and brain injuries suffered at birth. In making the ... Duke University, and Chief Executive Officer for Duke University ...
... medicine is one of today,s most exciting scientific and ... ,firsts, new rulings by regulatory bodies or ethical controversies. ... field, ethicists, legislators, the media and the public. ... are open to journalists and registration is free to ...
Cached Biology News:HSBC Climate Partnership yields initial research findings 2HSBC Climate Partnership yields initial research findings 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3ESHRE Annual Meeting, June 27-30 in Rome 2
... Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the fusion ... immunized (BALB/c X C57BL/6)F1 (CbyB6F1) ... mouse myeloma cellline. ...
... Mouse monoclonal [YPF19] to Yersinia pestis ... detect Yersinia pestis . ... Yersinia pestis vaccine strain ... antibody recognises Y.pestis F1 capsular antigen. ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: